![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY
Department of Pharmacology, Medical School, University of Patras, Patras, Greece
Many studies support the notion that protease-activated receptor (PAR)-1 plays a pivotal role in angiogenesis. However, direct evidence and understanding the molecular mechanisms involved were limited because PAR-1-specific antagonists have been developed only recently. In the present study, we evaluated the effects of two well characterized PAR-1 antagonists, SCH79797 ((N-3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]-methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine)) and RWJ56110 [(
S)-N-[(1S)-3-amino-1-[[(phenylmethyl)amino]carbonyl]propyl]-
-[[[[[1-(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluorobenzenepropanamide], in the angiogenic cascade. These antagonists suppressed both the basic angiogenesis and that stimulated by thrombin in the chick chorioallantoic membrane model in vivo. PAR-1 antagonists also abrogated tube formation in the in vitro Matrigel system. These inhibitory effects were dose-dependent and well correlated with the inhibitory effects of SCH79797 and RWJ56110 on primary endothelial cell proliferation and on the initiation of apoptosis. PAR-1 blockage resulted in inhibition of endothelial cell growth by increasing the sub-G0/G1 fraction and reducing the percentage of cells in the S phase. Consistent with this, PAR-1 antagonists reduced incorporation of [3H]thymidine in endothelial cells and blocked the phosphorylation of extracellular signal-regulated kinases in a fashion depending specifically on PAR-1 activation. Analysis by annexin V/propidium iodide staining and poly(ADP-ribose) polymerase cleavage revealed that PAR-1 blockage increased apoptotic cell death by a mechanism involving caspases. These results provide further evidence that PAR-1 is a key receptor that mediates angiogenesis and suggest PAR-1 as target for developing antiangiogenic agents with potential therapeutic application in cancer and other angiogenesis-related diseases.
Address correspondence to: Nikos E. Tsopanoglou, Department of Pharmacology, Medical School, University of Patras, 26500, Patras, Greece. E-mail: ntsopan{at}med.upatras.gr
This article has been cited by other articles:
![]() |
P. Zania, M. Papaconstantinou, C. S. Flordellis, M. E. Maragoudakis, and N. E. Tsopanoglou Thrombin mediates mitogenesis and survival of human endothelial cells through distinct mechanisms Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1215 - C1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Di Serio, S. Pellerito, and F. Tarantini Comments on "Blockade of Angiogenesis by Small Molecule Antagonists to Protease-Activated Receptor-1: Association with Endothelial Cell Growth Suppression and Induction of Apoptosis" J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 404 - 405. [Full Text] [PDF] |
||||
![]() |
N. E. Tsopanoglou and M. E. Maragoudakis Response to Comments on "Blockage of Angiogenesis by Small Molecule Antagonists to Protease-Activated Receptor-1: Association with Endothelial Cell Growth Suppression and Induction of Apoptosis" J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 406 - 407. [Full Text] [PDF] |
||||
![]() |
B. J. Hawkins, L. A. Solt, I. Chowdhury, A. S. Kazi, M. R. Abid, W. C. Aird, M. J. May, J. K. Foskett, and M. Madesh G Protein-Coupled Receptor Ca2+-Linked Mitochondrial Reactive Oxygen Species Are Essential for Endothelial/Leukocyte Adherence Mol. Cell. Biol., November 1, 2007; 27(21): 7582 - 7593. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Uusitalo-Jarvinen, T. Kurokawa, B. M. Mueller, P. Andrade-Gordon, M. Friedlander, and W. Ruf Role of Protease Activated Receptor 1 and 2 Signaling in Hypoxia-Induced Angiogenesis Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1456 - 1462. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Arora, T. K. Ricks, and J. Trejo Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer J. Cell Sci., March 15, 2007; 120(6): 921 - 928. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Salah, M. Maoz, E. Pokroy, M. Lotem, R. Bar-Shavit, and B. Uziely Protease-Activated Receptor-1 (hPar1), A Survival Factor Eliciting Tumor Progression Mol. Cancer Res., March 1, 2007; 5(3): 229 - 240. [Abstract] [Full Text] [PDF] |
||||